Competitive Advantage

Our patented technology, JAA-F11 specifically targets the alpha-linked form of a well-known disaccharide tumor marker, the Thomsen-Friedenreich glycoantigen (TF-Ag), found on the surface of 85% of all carcinomas.

Over half of all cancers are expected to be TF-Ag positive, which is a huge market.

TF-Ag is involved in spread of cancer cells. The mechanism of the involvement of TF-Ag in cancer metastasis is shown below. We believe that our highly specific JAA-F11 antibody which reacts with TF-Ag will create a survival advantage for patients with TF-Ag expressing tumors through direct killing of cancer cells and by blocking tumor cell spread. It also will be useful in imaging many cancers to detect metastasis. 

Immunohistochemical analysis shows specific binding to ~85% of the patients' tumors from patients with carcinomas including breast, lung, prostate, bladder, and ovarian.

Clinical translational research of humanized JAA-F11 for antibody therapy and diagnosis is currently underway. The crystal structure of JAA-F11 and carbohydrate threading was used to create humanized antibody constructs with the same or improved specificity.

The humanized construct selectively kills cancer cells by Antibody Directed Cellular Cytotoxicity, and can internalize rapidly to be used in antibody-drug conjugates. 

A stable cGMP cell line and cGMP antibody have been produced, and safety studies have been completed.

 See references below for more detail.

• Pipeline 1:  Imaging to find metastasis and to analyze indeterminant lesions in lung cancer diagnosis
• Pipeline 2: Humanized JAA-F11 construct for antibody-drug conjugate delivery for Breast Cancer Therapy
• Pipeline 4: Humanized JAA-F11 for direct antibody therapy of Lung Cancer
• Pipeline 5: Humanized JAA-F11 construct for antibody-drug conjugate delivery for Lung Cancer Therapy 
• Pipeline 6: Humanized JAA-F11 for direct antibody therapy of Breast Cancer